
<document id="DBMI.pac197" origId="pac197">
	<sentence id="DBMI.pac197.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nZidovudine is an antiviral agent [see Clinical Pharmacology (12.4)]."/>
	<sentence id="DBMI.pac197.s1" origId="s1" text="12.3 Pharmacokinetics\n\nAbsorption and Bioavailability:  In adults, following oral administration, zidovudine is rapidly absorbed and extensively distributed, with peak serum concentrations occurring within 0.5 to 1.5 hours."/>
	<sentence id="DBMI.pac197.s2" origId="s2" text="The extent of absorption (AUC) was equivalent when zidovudine was administered as zidovudine tablets or syrup compared with zidovudine capsules."/>
	<sentence id="DBMI.pac197.s3" origId="s3" text="The pharmacokinetic properties of zidovudine in fasting adult patients are summarized in Table 6."/>
	<sentence id="DBMI.pac197.s4" origId="s4" text="Distribution:  The apparent volume of distribution of zidovudine, following oral administration, is 1.6  0.6 L/kg; and binding to plasma protein is low, &lt;38% (Table 6)."/>
	<sentence id="DBMI.pac197.s5" origId="s5" text="Metabolism and Elimination:  Zidovudine is primarily eliminated by hepatic metabolism."/>
	<sentence id="DBMI.pac197.s6" origId="s6" text="The major metabolite of zidovudine is GZDV."/>
	<sentence id="DBMI.pac197.s7" origId="s7" text="GZDV AUC is about 3-fold greater than the zidovudine AUC."/>
	<sentence id="DBMI.pac197.s8" origId="s8" text="Urinary recovery of zidovudine and GZDV accounts for 14% and 74%, respectively, of the dose following oral administration."/>
	<sentence id="DBMI.pac197.s9" origId="s9" text="A second metabolite, 3'-amino-3'-deoxythymidine (AMT), has been identified in the plasma following single-dose intravenous (IV) administration of zidovudine."/>
	<sentence id="DBMI.pac197.s10" origId="s10" text="The AMT AUC was one fifth of the zidovudine AUC."/>
	<sentence id="DBMI.pac197.s11" origId="s11" text="Pharmacokinetics of zidovudine were dose independent at oral dosing regimens ranging from 2 mg/kg every 8 hours to 10 mg/kg every 4 hours."/>
	<sentence id="DBMI.pac197.s12" origId="s12" text="Effect of Food on Absorption:  Zidovudine may be administered with or without food."/>
	<sentence id="DBMI.pac197.s13" origId="s13" text="The extent of zidovudine absorption (AUC) was similar when a single dose of zidovudine was administered with food."/>
	<sentence id="DBMI.pac197.s14" origId="s14" text="Special Populations:  Renal Impairment:  Zidovudine clearance was decreased resulting in increased zidovudine and GZDV half-life and AUC in patients with impaired renal function (n = 14) following a single 200 mg oral dose (Table 7)."/>
	<sentence id="DBMI.pac197.s15" origId="s15" text="Plasma concentrations of AMT were not determined."/>
	<sentence id="DBMI.pac197.s16" origId="s16" text="A dose adjustment should not be necessary for patients with creatinine clearance (CrCl) 15 mL/min."/>
	<sentence id="DBMI.pac197.s17" origId="s17" text="Hemodialysis and Peritoneal Dialysis:  The pharmacokinetics and tolerance of zidovudine were evaluated in a multiple-dose study in patients undergoing hemodialysis (n = 5) or peritoneal dialysis (n = 6) receiving escalating doses up to 200 mg 5 times daily for 8 weeks."/>
	<sentence id="DBMI.pac197.s18" origId="s18" text="Daily doses of 500 mg or less were well tolerated despite significantly elevated GZDV plasma concentrations."/>
	<sentence id="DBMI.pac197.s19" origId="s19" text="Apparent zidovudine oral clearance was approximately 50% of that reported in patients with normal renal function."/>
	<sentence id="DBMI.pac197.s20" origId="s20" text="Hemodialysis and peritoneal dialysis appeared to have a negligible effect on the removal of zidovudine, whereas GZDV elimination was enhanced."/>
	<sentence id="DBMI.pac197.s21" origId="s21" text="A dosage adjustment is recommended for patients undergoing hemodialysis or peritoneal dialysis [see Dosage and Administration (2.4)]."/>
	<sentence id="DBMI.pac197.s22" origId="s22" text="Hepatic Impairment:  Data describing the effect of hepatic impairment on the pharmacokinetics of zidovudine are limited."/>
	<sentence id="DBMI.pac197.s23" origId="s23" text="However, because zidovudine is eliminated primarily by hepatic metabolism, it is expected that zidovudine clearance would be decreased and plasma concentrations would be increased following administration of the recommended adult doses to patients with hepatic impairment [see Dosage and Administration (2.5)]."/>
	<sentence id="DBMI.pac197.s24" origId="s24" text="Pediatric Patients:  Zidovudine pharmacokinetics have been evaluated in HIV-1-infected pediatric patients (Table 8)."/>
	<sentence id="DBMI.pac197.s25" origId="s25" text="Patients 3 Months to 12 Years of Age:  Overall, zidovudine pharmacokinetics in pediatric patients greater than 3 months of age are similar to those in adult patients."/>
	<sentence id="DBMI.pac197.s26" origId="s26" text="Proportional increases in plasma zidovudine concentrations were observed following administration of oral solution from 90 to 240 mg/m2 every 6 hours."/>
	<sentence id="DBMI.pac197.s27" origId="s27" text="Oral bioavailability, terminal half-life, and oral clearance were comparable to adult values."/>
	<sentence id="DBMI.pac197.s28" origId="s28" text="As in adult patients, the major route of elimination was by metabolism to GZDV."/>
	<sentence id="DBMI.pac197.s29" origId="s29" text="After intravenous dosing, about 29% of the dose was excreted in the urine unchanged, and about 45% of the dose was excreted as GZDV [see Dosage and Administration (2.1)]."/>
	<sentence id="DBMI.pac197.s30" origId="s30" text="Patients &lt;3 Months of Age:  Zidovudine pharmacokinetics have been evaluated in pediatric patients from birth to 3 months of life."/>
	<sentence id="DBMI.pac197.s31" origId="s31" text="Zidovudine elimination was determined immediately following birth in 8 neonates who were exposed to zidovudine in utero."/>
	<sentence id="DBMI.pac197.s32" origId="s32" text="The half-life was 13  5.8 hours."/>
	<sentence id="DBMI.pac197.s33" origId="s33" text="In neonates 14 days old, bioavailability was greater, total body clearance was slower, and half-life was longer than in pediatric patients &gt;14 days old."/>
	<sentence id="DBMI.pac197.s34" origId="s34" text="For dose recommendations for neonates [see Dosage and Administration (2.2)]."/>
	<sentence id="DBMI.pac197.s35" origId="s35" text="Pregnancy:  Zidovudine pharmacokinetics have been studied in a Phase I study of 8 women during the last trimester of pregnancy."/>
	<sentence id="DBMI.pac197.s36" origId="s36" text="Zidovudine pharmacokinetics were similar to those of nonpregnant adults."/>
	<sentence id="DBMI.pac197.s37" origId="s37" text="Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery [see Use in Specific Populations (8.1)]."/>
	<sentence id="DBMI.pac197.s38" origId="s38" text="Although data are limited, methadone maintenance therapy in 5 pregnant women did not appear to alter zidovudine pharmacokinetics."/>
	<sentence id="DBMI.pac197.s39" origId="s39" text="Nursing Mothers:  The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1."/>
	<sentence id="DBMI.pac197.s40" origId="s40" text="After administration of a single dose of 200 mg zidovudine to 13 HIV-1-infected women, the mean concentration of zidovudine was similar in human milk and serum [see Use In Specific Populations (8.3)]."/>
	<sentence id="DBMI.pac197.s41" origId="s41" text="Geriatric Patients:  Zidovudine pharmacokinetics have not been studied in patients over 65 years of age."/>
	<sentence id="DBMI.pac197.s42" origId="s42" text="Gender:  A pharmacokinetic study in healthy male (n = 12) and female (n = 12) subjects showed no differences in zidovudine exposure (AUC) when a single dose of zidovudine was administered as the 300 mg zidovudine tablet."/>
	<sentence id="DBMI.pac197.s43" origId="s43" text="Drug Interactions:  [See Drug Interactions (7)]."/>
	<sentence id="DBMI.pac197.s44" origId="s44" text="Phenytoin:  Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented.">
		<entity charOffset="5923-5934" id="DBMI.pac197.s44.e0" origId="s44.e0" text="zidovudine " type="Active ingredient"/>
		<entity charOffset="5843-5853" id="DBMI.pac197.s44.e1" origId="s44.e1" text="Phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac197.s44.e0" e2="DBMI.pac197.s44.e1" id="DBMI.pac197.s44.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Phenytoin " precipitant="zidovudine "/>
		<pair e1="DBMI.pac197.s44.e1" e2="DBMI.pac197.s44.e0" id="DBMI.pac197.s44.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac197.s45" origId="s45" text="However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed.">
		<entity charOffset="6138-6149" id="DBMI.pac197.s45.e0" origId="s45.e0" text="zidovudine " type="Active ingredient"/>
		<entity charOffset="6093-6103" id="DBMI.pac197.s45.e1" origId="s45.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac197.s45.e0" e2="DBMI.pac197.s45.e1" id="DBMI.pac197.s45.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="zidovudine "/>
		<pair e1="DBMI.pac197.s45.e1" e2="DBMI.pac197.s45.e0" id="DBMI.pac197.s45.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac197.s46" origId="s46" text="Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.">
		<entity charOffset="6286-6296" id="DBMI.pac197.s46.e0" origId="s46.e0" text="phenytoin " type="Active ingredient"/>
		<entity charOffset="6299-6310" id="DBMI.pac197.s46.e1" origId="s46.e1" text="zidovudine " type="Active ingredient"/>
		<pair e1="DBMI.pac197.s46.e0" e2="DBMI.pac197.s46.e1" id="DBMI.pac197.s46.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="zidovudine " precipitant="phenytoin "/>
		<pair e1="DBMI.pac197.s46.e1" e2="DBMI.pac197.s46.e0" id="DBMI.pac197.s46.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac197.s47" origId="s47" text="Ribavirin:  In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine."/>
	<sentence id="DBMI.pac197.s48" origId="s48" text="However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)].">
		<entity charOffset="6728-6738" id="DBMI.pac197.s48.e0" origId="s48.e0" text="ribavirin " type="Active ingredient"/>
		<entity charOffset="6763-6773" id="DBMI.pac197.s48.e1" origId="s48.e1" text="stavudine " type="Active ingredient"/>
		<entity charOffset="6786-6797" id="DBMI.pac197.s48.e2" origId="s48.e2" text="zidovudine " type="Active ingredient"/>
		<entity charOffset="6742-6753" id="DBMI.pac197.s48.e3" origId="s48.e3" text="lamivudine " type="Active ingredient"/>
		<pair e1="DBMI.pac197.s48.e0" e2="DBMI.pac197.s48.e1" id="DBMI.pac197.s48.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="stavudine " precipitant="ribavirin "/>
		<pair e1="DBMI.pac197.s48.e0" e2="DBMI.pac197.s48.e2" id="DBMI.pac197.s48.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="zidovudine " precipitant="ribavirin "/>
		<pair e1="DBMI.pac197.s48.e0" e2="DBMI.pac197.s48.e3" id="DBMI.pac197.s48.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lamivudine " precipitant="ribavirin "/>
		<pair e1="DBMI.pac197.s48.e1" e2="DBMI.pac197.s48.e0" id="DBMI.pac197.s48.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e1" e2="DBMI.pac197.s48.e2" id="DBMI.pac197.s48.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e1" e2="DBMI.pac197.s48.e3" id="DBMI.pac197.s48.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e2" e2="DBMI.pac197.s48.e0" id="DBMI.pac197.s48.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e2" e2="DBMI.pac197.s48.e1" id="DBMI.pac197.s48.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e2" e2="DBMI.pac197.s48.e3" id="DBMI.pac197.s48.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e3" e2="DBMI.pac197.s48.e0" id="DBMI.pac197.s48.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e3" e2="DBMI.pac197.s48.e1" id="DBMI.pac197.s48.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.s48.e3" e2="DBMI.pac197.s48.e2" id="DBMI.pac197.s48.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac197.s49" origId="s49" text="12.4 Microbiology\n\nMechanism of Action:  Zidovudine is a synthetic nucleoside analogue."/>
	<sentence id="DBMI.pac197.s50" origId="s50" text="Intracellularly, zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP)."/>
	<sentence id="DBMI.pac197.s51" origId="s51" text="The principal mode of action of ZDV-TP is inhibition of reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue."/>
	<sentence id="DBMI.pac197.s52" origId="s52" text="ZDV-TP is a weak inhibitor of the cellular DNA polymerases  and  and has been reported to be incorporated into the DNA of cells in culture."/>
	<sentence id="DBMI.pac197.s53" origId="s53" text="Antiviral Activity:  The antiviral activity of zidovudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood lymphocytes)."/>
	<sentence id="DBMI.pac197.s54" origId="s54" text="The EC50 and EC90 values for zidovudine were 0.01 to 0.49 M (1 M = 0.27 mcg/mL) and 0.1 to 9 M, respectively."/>
	<sentence id="DBMI.pac197.s55" origId="s55" text="HIV-1 from therapy-naive subjects with no mutations associated with resistance gave median EC50 values of 0.011 M (range: 0.005 to 0.11 M) from Virco (n = 92 baseline samples from COLA40263) and 0.0017 M (0.006 to 0.034 M) from Monogram Biosciences (n = 135 baseline samples from ESS30009)."/>
	<sentence id="DBMI.pac197.s56" origId="s56" text="The EC50 values of zidovudine against different HIV-1 clades (A-G) ranged from 0.00018 to 0.02 M, and against HIV-2 isolates from 0.00049 to 0.004 M. In cell culture drug combination studies, zidovudine demonstrates synergistic activity with the nucleoside reverse transcriptase inhibitors abacavir, didanosine, and lamivudine; the non-nucleoside reverse transcriptase inhibitors delavirdine and nevirapine; and the protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir; and additive activity with interferon alfa."/>
	<sentence id="DBMI.pac197.s57" origId="s57" text="Ribavirin has been found to inhibit the phosphorylation of zidovudine in cell culture."/>
	<sentence id="DBMI.pac197.s58" origId="s58" text="Resistance:  Genotypic analyses of the isolates selected in cell culture and recovered from zidovudine-treated patients showed mutations in the HIV-1 RT gene resulting in 6 amino acid substitutions (M41L, D67N, K70R, L210W, T215Y or F, and K219Q) that confer zidovudine resistance."/>
	<sentence id="DBMI.pac197.s59" origId="s59" text="In general, higher levels of resistance were associated with greater number of amino acid substitutions."/>
	<sentence id="DBMI.pac197.s60" origId="s60" text="In some patients harboring zidovudine-resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12 weeks of treatment with lamivudine and zidovudine."/>
	<sentence id="DBMI.pac197.s61" origId="s61" text="Combination therapy with lamivudine plus zidovudine delayed the emergence of substitutions conferring resistance to zidovudine."/>
	<sentence id="DBMI.pac197.s62" origId="s62" text="Cross-Resistance:  In a study of 167 HIV-1-infected patients, isolates (n = 2) with multi-drug resistance to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine were recovered from patients treated for 1 year with zidovudine plus didanosine or zidovudine plus zalcitabine."/>
	<sentence id="DBMI.pac197.s63" origId="s63" text="The pattern of resistance-associated amino acid substitutions with such combination therapies was different (A62V, V75I, F77L, F116Y, Q151M) from the pattern with zidovudine monotherapy, with the Q151M substitution being most commonly associated with multi-drug resistance."/>
	<sentence id="DBMI.pac197.s64" origId="s64" text="The substitution at codon 151 in combination with substitutions at 62, 75, 77, and 116 results in a virus with reduced susceptibility to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine."/>
	<sentence id="DBMI.pac197.s65" origId="s65" text="Thymidine analogue mutations (TAMs) are selected by zidovudine and confer cross-resistance to abacavir, didanosine, stavudine, tenofovir, and zalcitabine."/>
	<sentencespan id="DBMI.pac197.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nZidovudine is an antiviral agent [see Clinical Pharmacology (12.4)]. 12.3 Pharmacokinetics\n\nAbsorption and Bioavailability:  In adults, following oral administration, zidovudine is rapidly absorbed and extensively distributed, with peak serum concentrations occurring within 0.5 to 1.5 hours. The extent of absorption (AUC) was equivalent when zidovudine was administered as zidovudine tablets or syrup compared with zidovudine capsules."/>
	<sentencespan id="DBMI.pac197.sp1" origId="sp1" text="The pharmacokinetic properties of zidovudine in fasting adult patients are summarized in Table 6. Distribution:  The apparent volume of distribution of zidovudine, following oral administration, is 1.6  0.6 L/kg; and binding to plasma protein is low, &lt;38% (Table 6). Metabolism and Elimination:  Zidovudine is primarily eliminated by hepatic metabolism."/>
	<sentencespan id="DBMI.pac197.sp2" origId="sp2" text="The major metabolite of zidovudine is GZDV. GZDV AUC is about 3-fold greater than the zidovudine AUC. Urinary recovery of zidovudine and GZDV accounts for 14% and 74%, respectively, of the dose following oral administration."/>
	<sentencespan id="DBMI.pac197.sp3" origId="sp3" text="A second metabolite, 3'-amino-3'-deoxythymidine (AMT), has been identified in the plasma following single-dose intravenous (IV) administration of zidovudine. The AMT AUC was one fifth of the zidovudine AUC. Pharmacokinetics of zidovudine were dose independent at oral dosing regimens ranging from 2 mg/kg every 8 hours to 10 mg/kg every 4 hours."/>
	<sentencespan id="DBMI.pac197.sp4" origId="sp4" text="Effect of Food on Absorption:  Zidovudine may be administered with or without food. The extent of zidovudine absorption (AUC) was similar when a single dose of zidovudine was administered with food. Special Populations:  Renal Impairment:  Zidovudine clearance was decreased resulting in increased zidovudine and GZDV half-life and AUC in patients with impaired renal function (n = 14) following a single 200 mg oral dose (Table 7)."/>
	<sentencespan id="DBMI.pac197.sp5" origId="sp5" text="Plasma concentrations of AMT were not determined. A dose adjustment should not be necessary for patients with creatinine clearance (CrCl) 15 mL/min. Hemodialysis and Peritoneal Dialysis:  The pharmacokinetics and tolerance of zidovudine were evaluated in a multiple-dose study in patients undergoing hemodialysis (n = 5) or peritoneal dialysis (n = 6) receiving escalating doses up to 200 mg 5 times daily for 8 weeks."/>
	<sentencespan id="DBMI.pac197.sp6" origId="sp6" text="Daily doses of 500 mg or less were well tolerated despite significantly elevated GZDV plasma concentrations. Apparent zidovudine oral clearance was approximately 50% of that reported in patients with normal renal function. Hemodialysis and peritoneal dialysis appeared to have a negligible effect on the removal of zidovudine, whereas GZDV elimination was enhanced."/>
	<sentencespan id="DBMI.pac197.sp7" origId="sp7" text="A dosage adjustment is recommended for patients undergoing hemodialysis or peritoneal dialysis [see Dosage and Administration (2.4)]. Hepatic Impairment:  Data describing the effect of hepatic impairment on the pharmacokinetics of zidovudine are limited. However, because zidovudine is eliminated primarily by hepatic metabolism, it is expected that zidovudine clearance would be decreased and plasma concentrations would be increased following administration of the recommended adult doses to patients with hepatic impairment [see Dosage and Administration (2.5)]."/>
	<sentencespan id="DBMI.pac197.sp8" origId="sp8" text="Pediatric Patients:  Zidovudine pharmacokinetics have been evaluated in HIV-1-infected pediatric patients (Table 8). Patients 3 Months to 12 Years of Age:  Overall, zidovudine pharmacokinetics in pediatric patients greater than 3 months of age are similar to those in adult patients. Proportional increases in plasma zidovudine concentrations were observed following administration of oral solution from 90 to 240 mg/m2 every 6 hours."/>
	<sentencespan id="DBMI.pac197.sp9" origId="sp9" text="Oral bioavailability, terminal half-life, and oral clearance were comparable to adult values. As in adult patients, the major route of elimination was by metabolism to GZDV. After intravenous dosing, about 29% of the dose was excreted in the urine unchanged, and about 45% of the dose was excreted as GZDV [see Dosage and Administration (2.1)]."/>
	<sentencespan id="DBMI.pac197.sp10" origId="sp10" text="Patients &lt;3 Months of Age:  Zidovudine pharmacokinetics have been evaluated in pediatric patients from birth to 3 months of life. Zidovudine elimination was determined immediately following birth in 8 neonates who were exposed to zidovudine in utero. The half-life was 13  5.8 hours."/>
	<sentencespan id="DBMI.pac197.sp11" origId="sp11" text="In neonates 14 days old, bioavailability was greater, total body clearance was slower, and half-life was longer than in pediatric patients &gt;14 days old. For dose recommendations for neonates [see Dosage and Administration (2.2)]. Pregnancy:  Zidovudine pharmacokinetics have been studied in a Phase I study of 8 women during the last trimester of pregnancy."/>
	<sentencespan id="DBMI.pac197.sp12" origId="sp12" text="Zidovudine pharmacokinetics were similar to those of nonpregnant adults. Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery [see Use in Specific Populations (8.1)]. Although data are limited, methadone maintenance therapy in 5 pregnant women did not appear to alter zidovudine pharmacokinetics."/>
	<sentencespan id="DBMI.pac197.sp13" origId="sp13" text="Nursing Mothers:  The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1. After administration of a single dose of 200 mg zidovudine to 13 HIV-1-infected women, the mean concentration of zidovudine was similar in human milk and serum [see Use In Specific Populations (8.3)]. Geriatric Patients:  Zidovudine pharmacokinetics have not been studied in patients over 65 years of age."/>
	<sentencespan id="DBMI.pac197.sp14" origId="sp14" text="Gender:  A pharmacokinetic study in healthy male (n = 12) and female (n = 12) subjects showed no differences in zidovudine exposure (AUC) when a single dose of zidovudine was administered as the 300 mg zidovudine tablet. Drug Interactions:  [See Drug Interactions (7)]. Phenytoin:  Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented.">
		<entity charOffset="5923-5934" id="DBMI.pac197.sp14.e0" origId="sp14.e0" text="zidovudine " type="Active ingredient"/>
		<entity charOffset="5843-5853" id="DBMI.pac197.sp14.e1" origId="sp14.e1" text="Phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac197.sp14.e0" e2="DBMI.pac197.sp14.e1" id="DBMI.pac197.sp14.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Phenytoin " precipitant="zidovudine "/>
		<pair e1="DBMI.pac197.sp14.e1" e2="DBMI.pac197.sp14.e0" id="DBMI.pac197.sp14.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac197.sp15" origId="sp15" text="However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed. Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin. Ribavirin:  In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine.">
		<entity charOffset="6138-6149" id="DBMI.pac197.sp15.e0" origId="sp15.e0" text="zidovudine " type="Active ingredient"/>
		<entity charOffset="6093-6103" id="DBMI.pac197.sp15.e1" origId="sp15.e1" text="phenytoin " type="Active ingredient"/>
		<pair e1="DBMI.pac197.sp15.e0" e2="DBMI.pac197.sp15.e1" id="DBMI.pac197.sp15.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin " precipitant="zidovudine "/>
		<pair e1="DBMI.pac197.sp15.e1" e2="DBMI.pac197.sp15.e0" id="DBMI.pac197.sp15.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="zidovudine " precipitant="phenytoin "/>
	</sentencespan>
	<sentencespan id="DBMI.pac197.sp16" origId="sp16" text="However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)]. 12.4 Microbiology\n\nMechanism of Action:  Zidovudine is a synthetic nucleoside analogue. Intracellularly, zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP).">
		<entity charOffset="6728-6738" id="DBMI.pac197.sp16.e0" origId="sp16.e0" text="ribavirin " type="Active ingredient"/>
		<entity charOffset="6763-6773" id="DBMI.pac197.sp16.e1" origId="sp16.e1" text="stavudine " type="Active ingredient"/>
		<entity charOffset="6786-6797" id="DBMI.pac197.sp16.e2" origId="sp16.e2" text="zidovudine " type="Active ingredient"/>
		<entity charOffset="6742-6753" id="DBMI.pac197.sp16.e3" origId="sp16.e3" text="lamivudine " type="Active ingredient"/>
		<pair e1="DBMI.pac197.sp16.e0" e2="DBMI.pac197.sp16.e1" id="DBMI.pac197.sp16.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="stavudine " precipitant="ribavirin "/>
		<pair e1="DBMI.pac197.sp16.e0" e2="DBMI.pac197.sp16.e2" id="DBMI.pac197.sp16.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="zidovudine " precipitant="ribavirin "/>
		<pair e1="DBMI.pac197.sp16.e0" e2="DBMI.pac197.sp16.e3" id="DBMI.pac197.sp16.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lamivudine " precipitant="ribavirin "/>
		<pair e1="DBMI.pac197.sp16.e1" e2="DBMI.pac197.sp16.e0" id="DBMI.pac197.sp16.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e1" e2="DBMI.pac197.sp16.e2" id="DBMI.pac197.sp16.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e1" e2="DBMI.pac197.sp16.e3" id="DBMI.pac197.sp16.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e2" e2="DBMI.pac197.sp16.e0" id="DBMI.pac197.sp16.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e2" e2="DBMI.pac197.sp16.e1" id="DBMI.pac197.sp16.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e2" e2="DBMI.pac197.sp16.e3" id="DBMI.pac197.sp16.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e3" e2="DBMI.pac197.sp16.e0" id="DBMI.pac197.sp16.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e3" e2="DBMI.pac197.sp16.e1" id="DBMI.pac197.sp16.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac197.sp16.e3" e2="DBMI.pac197.sp16.e2" id="DBMI.pac197.sp16.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac197.sp17" origId="sp17" text="The principal mode of action of ZDV-TP is inhibition of reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. ZDV-TP is a weak inhibitor of the cellular DNA polymerases  and  and has been reported to be incorporated into the DNA of cells in culture. Antiviral Activity:  The antiviral activity of zidovudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood lymphocytes)."/>
	<sentencespan id="DBMI.pac197.sp18" origId="sp18" text="The EC50 and EC90 values for zidovudine were 0.01 to 0.49 M (1 M = 0.27 mcg/mL) and 0.1 to 9 M, respectively. HIV-1 from therapy-naive subjects with no mutations associated with resistance gave median EC50 values of 0.011 M (range: 0.005 to 0.11 M) from Virco (n = 92 baseline samples from COLA40263) and 0.0017 M (0.006 to 0.034 M) from Monogram Biosciences (n = 135 baseline samples from ESS30009). The EC50 values of zidovudine against different HIV-1 clades (A-G) ranged from 0.00018 to 0.02 M, and against HIV-2 isolates from 0.00049 to 0.004 M. In cell culture drug combination studies, zidovudine demonstrates synergistic activity with the nucleoside reverse transcriptase inhibitors abacavir, didanosine, and lamivudine; the non-nucleoside reverse transcriptase inhibitors delavirdine and nevirapine; and the protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir; and additive activity with interferon alfa."/>
	<sentencespan id="DBMI.pac197.sp19" origId="sp19" text="Ribavirin has been found to inhibit the phosphorylation of zidovudine in cell culture. Resistance:  Genotypic analyses of the isolates selected in cell culture and recovered from zidovudine-treated patients showed mutations in the HIV-1 RT gene resulting in 6 amino acid substitutions (M41L, D67N, K70R, L210W, T215Y or F, and K219Q) that confer zidovudine resistance. In general, higher levels of resistance were associated with greater number of amino acid substitutions."/>
	<sentencespan id="DBMI.pac197.sp20" origId="sp20" text="In some patients harboring zidovudine-resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12 weeks of treatment with lamivudine and zidovudine. Combination therapy with lamivudine plus zidovudine delayed the emergence of substitutions conferring resistance to zidovudine. Cross-Resistance:  In a study of 167 HIV-1-infected patients, isolates (n = 2) with multi-drug resistance to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine were recovered from patients treated for 1 year with zidovudine plus didanosine or zidovudine plus zalcitabine."/>
	<sentencespan id="DBMI.pac197.sp21" origId="sp21" text="The pattern of resistance-associated amino acid substitutions with such combination therapies was different (A62V, V75I, F77L, F116Y, Q151M) from the pattern with zidovudine monotherapy, with the Q151M substitution being most commonly associated with multi-drug resistance. The substitution at codon 151 in combination with substitutions at 62, 75, 77, and 116 results in a virus with reduced susceptibility to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine. Thymidine analogue mutations (TAMs) are selected by zidovudine and confer cross-resistance to abacavir, didanosine, stavudine, tenofovir, and zalcitabine."/>
</document>
